Arcellx, Inc. (ACLX) |
|
20.24 0.54 (2.74%)
|
12-02 16:00 |
|
Open: |
19.5 |
Pre. Close: |
19.7 |
|
High:
|
20.38 |
Low:
|
18.71 |
|
Volume:
|
530,225 |
Market Cap:
|
888(M) |
|
|
|
Technical analysis |
as of: 2022-12-02 4:20:39 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 25.78  One year: 28.21 |
| Support: |
Support1: 18.7 Support2: 15.56 |
| Resistance: |
Resistance1: 22.07 Resistance2: 24.15 |
| Pivot: |
20.78 |
| Moving Average: |
MA(5): 20 MA(20): 21.13
MA(100): 19.71 MA(250): 0 |
| MACD: |
MACD(12,26): -0.2 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 19.5 %D(3): 16.9 |
| RSI: |
RSI(14): 47.1 |
| 52-week: |
High: 26.9 Low: 6.03 |
| Average Vol(K): |
3-Month: 530 (K) 10-Days: 426 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ACLX ] has closed above bottom band by 33.9%. Bollinger Bands are 17.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
20.43 - 20.56 |
20.56 - 20.69 |
|
Low:
|
18.39 - 18.56 |
18.56 - 18.7 |
|
Close:
|
19.97 - 20.25 |
20.25 - 20.49 |
|
Company Description |
|
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland. |
Headline News |
Wed, 30 Nov 2022
We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely - Yahoo Finance UK
Mon, 21 Nov 2022
Should You Accumulate Arcellx Inc (ACLX) in Biotechnology Industry? - InvestorsObserver
Thu, 17 Nov 2022
Arcellx, Inc. (NASDAQ:ACLX) Short Interest Update - MarketBeat
Thu, 17 Nov 2022
Companies Like Arcellx (NASDAQ:ACLX) Are In A Position To Invest In Growth - Simply Wall St
Tue, 15 Nov 2022
Arcellx GAAP EPS of -$2.12 (NASDAQ:ACLX) - Seeking Alpha
Mon, 14 Nov 2022
Arcellx Reports Third Quarter 2022 Financial Results and Business Progress - PR Newswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
44 (M) |
| Shares Float |
20 (M) |
|
% Held by Insiders
|
8.8 (%) |
|
% Held by Institutions
|
95.2 (%) |
|
Shares Short
|
2,730 (K) |
|
Shares Short P.Month
|
3,030 (K) |
Stock Financials |
|
EPS
|
-15.5 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
5.38 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-44.6 |
|
Return on Equity (ttm)
|
-93.2 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-3.9 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-93 (M) |
|
Levered Free Cash Flow
|
-99 (M) |
Stock Valuations |
|
PE Ratio
|
-1.31 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
3.75 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-9.51 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
